High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients.

ABSTRACT: The relation between tumor mutation burden (TMB) and outcome of cancer patients receiving immunotherapy has been reported. This study aimed to evaluate the prognostic role of TMB in cancer patients receiving immunotherapy. Databases including Embase, PubMed, and the Cochrane library were systematically searched to identify potentially eligible studies until Sep 2018 without language limitation. Studies assessing high versus low TMB in predicting survival of various cancer patients were selected. The pooled analyses were conducted using hazard ratio (HR) of high versus low TMB for overall survival (OS) and progression-free survival (PFS), and the odds ratio (OR) for overall response rate (ORR). The primary endpoint was OS. Secondary outcomes were PFS and ORR. A total of 45 studies consistin

SUBMITTER: Cao D 

PROVIDER: S-EPMC6685508 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature